Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It develops Xanamem, an oral medication and inhibitor of the 11ß-HSD1 enzyme that achieves target engagement in the brain for the treatment of Alzheimer's disease, major depressive disorder, fragile x syndrome, and other neurological diseases. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.
Frequently asked questions
What sector does Actinogen Medical Limited (ATGGF) operate in?
Actinogen Medical Limited belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Actinogen Medical Limited (ATGGF) current stock price?
As of the latest data, Actinogen Medical Limited stock price is $0.04, with a previous close of $0.04.
What is Actinogen Medical Limited (ATGGF) current market capitalization?
Actinogen Medical Limited market cap is approximately 135.60 million.
What is Actinogen Medical Limited (ATGGF) EBITDA?
Actinogen Medical Limited EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -14.60 million.
Does Actinogen Medical Limited (ATGGF) pay dividends?
No. Actinogen Medical Limited does not pay a dividend.
What is Actinogen Medical Limited (ATGGF) beta (volatility) score?
Actinogen Medical Limited has a beta of 0.829, meaning its volatility is roughly in line with the market.